相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Effects of pemafibrate on glucose metabolism markers and liver function tests in patients with hypertriglyceridemia: a pooled analysis of six phase 2 and phase 3 randomized double-blind placebo-controlled clinical trials
Koutaro Yokote et al.
CARDIOVASCULAR DIABETOLOGY (2021)
Measuring Insulin Resistance in Humans
Vandhna R. Sharma et al.
HORMONE RESEARCH IN PAEDIATRICS (2021)
Triglyceride/High-Density Lipoprotein Cholesterol Ratio: A Clue to Metabolic Syndrome, Insulin Resistance, and Severe Atherosclerosis
M. Reza Azarpazhooh et al.
LIPIDS (2021)
Cardiovascular Harm From Egg Yolk and Meat: More Than Just Cholesterol and Saturated Fat
J. David Spence et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2021)
Interpreting the Results of Intention-to-Treat, Per-Protocol, and As-Treated Analyses of Clinical Trials
Valerie A. Smith et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association
Dawn O. Kleindorfer et al.
STROKE (2021)
Potential New Horizons for the Prevention of Cerebrovascular Diseases and Dementia
Leonardo Pantoni
JAMA NEUROLOGY (2019)
Pioglitazone Therapy in Patients With Stroke and Prediabetes A Post Hoc Analysis of the IRIS Randomized Clinical Trial
J. David Spence et al.
JAMA NEUROLOGY (2019)
The low dose (7.5 mg/day) pioglitazone is beneficial to the improvement in metabolic parameters without weight gain and an increase of risk for heart failure
Hiroki Adachi et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2017)
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA. IT): a randomised, multicentre trial
Olga Vaccaro et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
W. N. Kernan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Is Insulin Resistance a Feature of or a Primary Risk Factor for Cardiovascular Disease?
Markku Laakso
CURRENT DIABETES REPORTS (2015)
Initial combination therapy with metformin, pioglitazone and exenatide is more effective than sequential add-on therapy in subjects with new-onset diabetes. Results from the Efficacy and Durability of Initial Combination Therapy for Type 2 Diabetes (EDICT): a randomized trial
M. A. Abdul-Ghani et al.
DIABETES OBESITY & METABOLISM (2015)
Effect of low dose pioglitazone on glycemic control and insulin resistance in Type 2 diabetes: A randomized, double blind, clinical trial
Sujit Rajagopalan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis
Emma O. Billington et al.
DIABETOLOGIA (2015)
Beneficial Effects of Canagliflozin in Combination with Pioglitazone on Insulin Sensitivity in Rodent Models of Obese Type 2 Diabetes
Yoshinori Watanabe et al.
PLOS ONE (2015)
Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: Rationale and design of the Insulin Resistance Intervention after Stroke Trial
Catherine M. Viscoli et al.
AMERICAN HEART JOURNAL (2014)
Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial
C. S. Kovacs et al.
DIABETES OBESITY & METABOLISM (2014)
Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors
Aramesh Saremi et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2013)
Effect of Spironolactone and Amiloride on Thiazolidinedione-Induced Fluid Retention in South Indian Patients with Type 2 Diabetes
Vijay Viswanathan et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
An Updated Definition of Stroke for the 21st Century A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Ralph L. Sacco et al.
STROKE (2013)
Thiazolidinedione-Induced Fluid Retention: Recent Insights into the Molecular Mechanisms
Jerzy Beltowski et al.
PPAR RESEARCH (2013)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population
Wolfram Doehner et al.
INTERNATIONAL JOURNAL OF CARDIOLOGY (2012)
Third Universal Definition of Myocardial Infarction
Kristian Thygesen et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2012)
Insulin Resistance and Risk of Incident Cardiovascular Events in Adults without Diabetes: Meta-Analysis
Karin B. Gast et al.
PLOS ONE (2012)
Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
R. A. DeFronzo
DIABETOLOGIA (2010)
Effects of Pioglitazone on Intramyocellular Fat Metabolism in Patients with Type 2 Diabetes Mellitus
Mandeep Bajaj et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Relationship between urinary sodium excretion and pioglitazone-induced edema
Akinobu Nakamura et al.
JOURNAL OF DIABETES INVESTIGATION (2010)
Pleiotropic effects of thiazolidinediones on traditional and non-traditional atherosclerotic risk factors
G. Schernthaner
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2009)
Insulin sensitivity: modulation by nutrients and inflammation
Simon Schenk et al.
JOURNAL OF CLINICAL INVESTIGATION (2008)
Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet
Iris Shai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The effect of thiazolidinediones on BMD and osteoporosis
Allyson K. McDonough et al.
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2008)
Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke - Results from PROactive (PROspective pioglitAzone Clinical Trial in macroVascular Events 04)
Robert Wilcox et al.
STROKE (2007)
Thiazolidinediones improve β-cell function in type 2 diabetic patients
Amalia Gastaldelli et al.
AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM (2007)
The Anti-Atherogenic Effects of Thiazolidinediones
Lily Stojanovska et al.
CURRENT DIABETES REVIEWS (2007)
Insulin resistance and atherosclerosis
Clay F. Semenkovich
JOURNAL OF CLINICAL INVESTIGATION (2006)
Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes
H Sourij et al.
DIABETES CARE (2006)
Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepiride
G Derosa et al.
HYPERTENSION RESEARCH (2005)
Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial
JA Dormandy et al.
LANCET (2005)
Drug therapy: Thiazolidinediones
H Yki-Jarvinen
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke
WN Kernan et al.
NEUROLOGY (2003)
Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes - A 6-month randomized placebo-controlled dose-response study
S Aronoff et al.
DIABETES CARE (2000)
Effect of insulin on human aortic endothelial nitric oxide synthase
A Aljada et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2000)
分享论文
